For the quarter ended February 2025, Walgreens Boots Alliance (WBA) reported revenue of $38.59 billion, up 4.2% over the same period last year. EPS came in at $0.63, compared to $1.20 in the year-ago quarter.

The reported revenue represents a surprise of +1.75% over the Zacks Consensus Estimate of $37.92 billion. With the consensus EPS estimate being $0.53, the EPS surprise was +18.87%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Walgreens performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenues- U.S. Retail Pharmacy: $30.38 billion compared to the $29.57 billion average estimate based on four analysts. The reported number represents a change of +5.3% year over year.
• Revenues- U.S. Healthcare: $2.15 billion versus the four-analyst average estimate of $2.25 billion. The reported number represents a year-over-year change of -1.1%.
• Revenues- International: $6.06 billion versus $6.05 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +0.6% change.
• Adjusted operating income (loss)- U.S. Retail Pharmacy: $487 million versus $384.40 million estimated by three analysts on average.
• Adjusted operating income (loss)- International: $234 million compared to the $206.99 million average estimate based on three analysts.
• Adjusted operating income (loss)- U.S. Healthcare: $117 million compared to the $15.94 million average estimate based on three analysts.
• Adjusted operating income (loss)- Corporate and Other: -$52 million versus the two-analyst average estimate of -$52 million.

View all Key Company Metrics for Walgreens here>>>

Shares of Walgreens have returned -5.1% over the past month versus the Zacks S&P 500 composite's -12.2% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Walgreens Boots Alliance, Inc. (WBA) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research